Abstract
Background: Parthenolide (PN) has been reported to inhibit proliferation and induces apoptosis in a variety of cancer cells with different mechanisms. Nevertheless, to the best of our knowledge, its relative anticancer activity at lower doses has not been reported in HaCaT immortalized keratinocytes and A375 melanoma cells.
Objective and Method: The present study aimed to investigate the relative anticancer effects of PN by analysing its cytotoxicity, apoptosis and cell cycle arresting potentials in HaCaT and A375 cells.
Result: PN was found to be significantly cytotoxic with lower IC50 values of 1.45 µM and 2.9 µM (p<0.05) in HaCaT and A375 cells, respectively with nuclear disruption as evident by DAPI staining. A dose-dependent increase in DNA fragmentation indicated apoptotic cell death. Furthermore, the percentage of cells deposition at S (35.56 to 43.68%) and G0-G1 (27.15 to 56.44%) phases after 24 h of PN treatment, substantiate its cell cycle arresting potentials in HaCaT and A375 cells.
Conclusion: These comparative results provided substantial evidence to conclude the anticancer potential of PN, especially at lower dosages to induce cell death mechanisms in skin epidermal cells.
Keywords: Apoptosis, cell cycle arrest, DNA fragmentation, keratinocytes, melanoma, parthenolide.
Current Drug Discovery Technologies
Title:Relative In Vitro Potentials of Parthenolide to Induce Apoptosis and Cell Cycle Arrest in Skin Cancer Cells
Volume: 13 Issue: 1
Author(s): Vazhappilly C. George, Devanga R.N. Kumar and Rangasamy A. Kumar
Affiliation:
Keywords: Apoptosis, cell cycle arrest, DNA fragmentation, keratinocytes, melanoma, parthenolide.
Abstract: Background: Parthenolide (PN) has been reported to inhibit proliferation and induces apoptosis in a variety of cancer cells with different mechanisms. Nevertheless, to the best of our knowledge, its relative anticancer activity at lower doses has not been reported in HaCaT immortalized keratinocytes and A375 melanoma cells.
Objective and Method: The present study aimed to investigate the relative anticancer effects of PN by analysing its cytotoxicity, apoptosis and cell cycle arresting potentials in HaCaT and A375 cells.
Result: PN was found to be significantly cytotoxic with lower IC50 values of 1.45 µM and 2.9 µM (p<0.05) in HaCaT and A375 cells, respectively with nuclear disruption as evident by DAPI staining. A dose-dependent increase in DNA fragmentation indicated apoptotic cell death. Furthermore, the percentage of cells deposition at S (35.56 to 43.68%) and G0-G1 (27.15 to 56.44%) phases after 24 h of PN treatment, substantiate its cell cycle arresting potentials in HaCaT and A375 cells.
Conclusion: These comparative results provided substantial evidence to conclude the anticancer potential of PN, especially at lower dosages to induce cell death mechanisms in skin epidermal cells.
Export Options
About this article
Cite this article as:
George C. Vazhappilly, Kumar R.N. Devanga and Kumar A. Rangasamy, Relative In Vitro Potentials of Parthenolide to Induce Apoptosis and Cell Cycle Arrest in Skin Cancer Cells, Current Drug Discovery Technologies 2016; 13 (1) . https://dx.doi.org/10.2174/1570163813666160224124029
DOI https://dx.doi.org/10.2174/1570163813666160224124029 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: CPPM 2013 Onward: Building a Socio-Technical GPS for Global Personalized Medicine – A Welcome to Editors-In-Chief Adrian LLerena (Spain) and Ross A. McKinnon (Australia)
Current Pharmacogenomics and Personalized Medicine Metallothioneins and Cancer
Current Protein & Peptide Science Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Recent Patents on Anti-Cancer Drug Discovery Anticancer Activity of Lectins from <i>Bauhinia purpurea</i> and <i>Wisteria floribunda</i> on Breast Cancer MCF-7 Cell Lines
Protein & Peptide Letters Biomarkers for Systemic Therapy in Ovarian Cancer
Current Cancer Drug Targets Administration of Drug and Nutritional Components in Nano-Engineered Form to Increase Delivery Ratio and Reduce Current Inefficient Practice
Recent Patents on Drug Delivery & Formulation An Overview of the Chemistry and Pharmacological Potentials of Furanones Skeletons
Current Organic Chemistry Nutrition, Brain Aging, and Alzheimers Disease
Current Nutrition & Food Science Viral Latent Proteins as Targets for Kaposis Sarcoma and Kaposis Sarcoma-associated Herpesvirus (KSHV / HHV-8) Induced Lymphoma
Current Drug Targets - Infectious Disorders Putative Mechanisms of Action and Clinical Use of Lithium in Children and Adolescents: A Critical Review
Current Neuropharmacology Patents and the Development on Polymer based Nanomaterial (PAMAM Dendrimer) for Biomedical Applications
Recent Patents on Biomedical Engineering (Discontinued) Strategic Aspects of NPY-Based Monoclonal Antibodies for Diagnosis and Treatment of Breast Cancer
Current Protein & Peptide Science Utilities of Some Carbon Nucleophiles in Heterocyclic Synthesis
Current Organic Chemistry Imatinib Reduces the Vasculogenic Potential of Plastic Tumor Cells
Current Angiogenesis (Discontinued) Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: 'A Hard Days Night'
Current Pharmaceutical Design Mast Cells as Targets of Pimecrolimus
Current Pharmaceutical Design Recent Advances on Radionuclide Labeled Hypoxia-Imaging Agents
Current Pharmaceutical Design Killing the Messenger: Antisense DNA and siRNA
Current Drug Targets Nanomaterials for Photohyperthermia: A Review
Current Pharmaceutical Design